A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication.
Pharmacologic therapy for intermittent claudication in patients with peripheral artery disease (PAD) is limited. We aimed to determine the durability of cilostazol treatment response over time, treatment effects in various subpopulations, and long-term safety. This analysis pooled original data from nine randomized, controlled trials evaluating cilostazol in intermittent claudication, including 1258 subjects treated with cilostazol 100 mg bid. Analysis of covariance was used to compare differences in walking distance, and a pooled random-effects weighted mean difference in maximal walking distance (MWD) was determined. Temporal effects were analyzed by compiling data at 4-week intervals in studies of 24 weeks in duration. Cilostazol was associated with a 50.7% improvement from baseline in MWD compared with placebo (24.3%), with an absolute improvement of 42.1 meters greater than the improvement with placebo (p < 0.001) over a mean follow-up period of 20.4 weeks. Continued increases were demonstrated over the 24-week treatment period. These benefits were seen in all subgroups, after stratifying by age, sex, smoking status, duration of PAD, diabetes, hypertension, prior myocardial infarction, or beta-blocker use. Cilostazol did not increase the risk of all-cause mortality (RR 0.95 [0.68-1.35]). In conclusion, treatment with cilostazol achieves benefits in walking distance that are sustained at 24 weeks and observed irrespective of baseline clinical characteristics. Cilostazol demonstrated no increased risk of all-cause mortality.
Pande
Reena L
RL
Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. rpande@partners.org
Hiatt
William R
WR
Zhang
Peter
P
Hittel
Norbert
N
Creager
Mark A
MA
D000077407:Cilostazol; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy* / Q000401:mortality; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012307:Risk Factors; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D013812:Therapeutics; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol
Am J Med. 2000 Nov;109(7):523-30
11063952
Vasc Med. 1999;4(4):239-46
10613628
Circulation. 1989 Nov;80(5 Pt 2):III59-72
2680161
Thromb Res. 1990 Feb 15;57(4):617-23
2158154
J Atheroscler Thromb. 2003;10(2):93-8
12740483
N Engl J Med. 1991 Nov 21;325(21):1468-75
1944425
Circulation. 1998 Aug 18;98(7):678-86
9715861
Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1942-7
9848888
Pharmacology. 1988;36(5):313-20
2841693
Med Care. 1992 Jun;30(6):473-83
1593914
Vasc Endovascular Surg. 2002 Mar-Apr;36(2):83-91
11951094
Clin Pharmacol Ther. 2002 Apr;71(4):246-52
11956507
Am J Cardiol. 2002 Dec 15;90(12):1314-9
12480040
J Vasc Surg. 1998 Dec;28(6):1072-81
9845659
Br J Surg. 1997 Aug;84(8):1107-9
9278653
Med Sci Sports Exerc. 1992 Feb;24(2):163-70
1549004
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003748
18254032
J Vasc Surg. 1998 Feb;27(2):267-74; discussion 274-5
9510281
Arch Intern Med. 1999 Sep 27;159(17):2041-50
10510990
Angiology. 1993 Jan;44(1):1-10
8424578
J Vasc Surg. 2008 Feb;47(2):330-336
18155871
J Am Geriatr Soc. 2002 Dec;50(12):1939-46
12473004
JAMA. 1995 Sep 27;274(12):975-80
7674529